Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling

Trial Profile

Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs FP 1039 (Primary) ; Carboplatin; Cisplatin; Docetaxel; Paclitaxel; Pemetrexed
  • Indications Mesothelioma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 28 Sep 2017 to 24 Oct 2017.
    • 05 Oct 2017 Planned primary completion date changed from 28 Sep 2017 to 24 Oct 2017.
    • 12 Sep 2017 Results (data cutoff 17 Mar 2017, n=36) of analysis of patients with malignant pleural mesothelioma presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top